Clinical trial · Interventional
Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
Phase I Dose Escalation Study of a Hypofractionated Stereotactic Boost (HySBst) to the Primary Site in Patients With Stage II-III Non-small Cell Lung Cancer
NCT02252796CI-TRIAL-00033128HySBstterminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Investigator left institution
Summary
Brief summary (as posted)
This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Hypofractionated Stereotactic Boost | Radiation | — | UNRESOLVED |
| Image-guided IMRT | Radiation | — | UNRESOLVED |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Sub-group 1
- description
- HySBst to be delivered during week 1 with Chemo-radiation to be delivered weeks 2-7
- interventionNames
- Radiation: Hypofractionated Stereotactic Boost
- Drug: Carboplatin
- Drug: Paclitaxel
- Radiation: Image-guided IMRT
- type
- EXPERIMENTAL
- label
- Sub-group 2
- description
- Chemo-radiation to be delivered weeks 1-6 and HySBst to be delivered week 7
- interventionNames
- Radiation: Hypofractionated Stereotactic Boost
- Drug: Carboplatin
- Drug: Paclitaxel
- Radiation: Image-guided IMRT
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage II - III Non Small Cell Lung Cancer Exclusion Criteria: * Primary tumor directly invading into any mediastinal structures, such as the heart, major blood vessels, esophagus, trachea, and the proximal bronchial tree. * Prior chemotherapy for NSCLC * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. * Severe, active co-morbidity * Pregnancy or women of childbearing potential * Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin * Uncontrolled neuropathy ≥ grade 2.
References
Publications (0)
Data not yet available
No reference posted for this study.